PARP1 and ovarian serous adenocarcinoma: The PARP inhibitor olaparib has been shown to enhance the radiosensitization effect on high‐grade serous ovarian cancer, and inhibition of PARP1 seems to regulate the recombination of DNA strand breaks and affect the concentration of ROS.48, 49